You need to login...
If you are not registered...
| Subscribe to Krixos Health: | |
|
or call us on: +43 (0)1 27 63 015 or email: subscribe@krixos.com | |
Most viewed
- 1. Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data.
- 2. Sexual activity in men undergoing ADT for localized prostate cancer: a narrative literature review.
- 3. Follow-up of hereditary endometrial carcinoma caused by MLH3 gene mutation: a case report
- 4. ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting
- 5. Accent Therapeutics Presents Data Supporting Therapeutic Potential of First-in-Class DHX9 Inhibitor, ATX-559, and Novel KIF18A Inhibitor, ATX-295, at the AACR Annual Meeting 2025
- 6. Association of aggregate index of systemic inflammation with increased all-cause and cardiovascular mortality in female cancer patients
- 7. LSM2 drives glioma progression through alternative splicing dysregulation: a multi-omics approach to identify a potential therapeutic target
- 8. Human medicines European public assessment report (EPAR): Dazublys, trastuzumab, Status: Opinion
- 9. Novartis posts better-than-expected sales driven by medicine demand
- 10. Why brain metastases of breast cancer resist a promising candidate therapy
Last updated at 0:52 GMT
Hot News Makers
Health/Pharma Companies
- 37175.90
- 23345.43
- 11715.56
- 11362.29
- 11234.46
- 9230.81
- 8126.63
- 6711.06
- 5894.42
- 5883.08
Drugs, Treatments, Trials
- 10105.48
- 9054.74
- 5702.59
- 4937.37
- 4372.46
- 3898.50
- 3198.63
- 2842.67
- 2408.48
- 2085.02
Last updated at 0:10 GMT
